News >

Ruxolitinib Demonstrates Consistent Survival Benefit in Myelofibrosis

Published: Monday, Dec 19, 2016

Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD

Patients with intermediate/high-risk myelofibrosis (MF) had improved survival when treated long term with the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi), pooled data from 2 randomized trials showed.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication